Equillium, Inc. — Form 10-Q Summary
Reporting period: Quarter ended September 30, 2022; filed November 14, 2022. Equillium is a clinical-stage biotechnology company developing treatments for autoimmune and inflammatory disorders. It has no approved products and generated no revenue.
Financial performance and position
| Metric | Q3 2022 | Q3 2021 | Nine months 2022 | Nine months 2021 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $8.8 million | $7.0 million | $29.0 million | $18.8 million |
| Acquired in-process R&D expense | — | — | $23.0 million | — |
| General and administrative expense | $4.5 million | $2.9 million | $12.0 million | $8.6 million |
| Net loss | $13.7 million | $10.3 million | $65.2 million | $28.4 million |
| Basic and diluted loss per share | $0.40 | $0.35 | $1.95 | $0.99 |
- Liquidity: Cash, cash equivalents and short-term investments totaled $44.5 million at September 30, 2022, down from $80.7 million at December 31, 2021. Cash and cash equivalents were $25.7 million; short-term investments were $18.8 million.
- Cash flow: Operating activities used $36.5 million in the first nine months of 2022, versus $21.9 million in the comparable 2021 period. Investing activities provided $11.7 million, largely reflecting maturities of short-term investments; financing activities provided $0.1 million.
- Debt: Notes payable had a carrying value of $10.3 million, including $5.7 million classified as current. The $10.0 million term loan bears interest at the greater of 8.25% or prime plus 3.00%, matures June 2024, and began scheduled principal payments after its interest-only period ended September 30, 2022. The company reported compliance with loan covenants.
- Equity: Stockholders’ equity was $28.2 million, compared with $66.5 million at year-end 2021. Shares outstanding were 34.4 million at September 30, 2022, versus 29.5 million at December 31, 2021; the increase primarily reflected shares issued for the Bioniz acquisition.
Material changes and business developments
- Q3 R&D expense rose $1.8 million year over year, mainly from start-up costs for the pivotal Phase 3 EQUATOR aGVHD trial. Nine-month R&D expense increased $10.2 million, reflecting clinical and nonclinical development, higher personnel costs and Bioniz transaction expenses.
- Q3 G&A expense increased $1.6 million, principally from legal costs related to business development, employee compensation and overhead.
- Nine-month net loss included a $23.0 million noncash acquired in-process R&D charge for Bioniz, acquired in February 2022. The acquisition added clinical-stage candidates EQ101 and EQ102 and a discovery platform. Additional contingent payments may be due upon specified regulatory and commercialization milestones.
- Equillium issued 4.82 million shares at closing for Bioniz; up to approximately 0.88 million additional shares remained subject to adjustment and issuance under the merger agreement.
- At September 30, accumulated deficit was $175.2 million. The company expects losses and negative operating cash flows to continue as it funds development.
Outlook, risks and contingencies
- Management stated that available cash and investments, together with cash expected from the proposed Metacrine merger, should fund operations for at least 12 months from the filing date. This assessment depends on the merger closing on time and with sufficient net cash. If it does not, Equillium may seek financing through its equity line, ATM facility or partners, or scale back, delay or discontinue programs.
- The proposed Metacrine merger, announced September 6 and amended October 26, 2022, was expected to close in late 2022 or early 2023, subject to stockholder approvals, an effective Form S-4, customary conditions and Metacrine having at least $23 million of net cash at closing. The exchange formula uses an Equillium share-price floor of $2.70 and ceiling of $4.50. There is no assurance the merger will close. Qualifying termination circumstances could trigger a $1.75 million fee payable by Equillium or a $1.25 million fee payable by Metacrine.
- Equillium reported plans to discuss assuming Metacrine’s debt facility, with $15 million outstanding, and retiring its existing $10 million facility. The arrangement was not assured; management described different expected cash and debt outcomes depending on whether it was completed.
- Key programs include itolizumab in Phase 3 development for aGVHD and in lupus nephritis studies; EQ102 began a Phase 1 study in September 2022. The filing also reports that EQ101’s Phase 2 alopecia areata study began in November 2022, after the quarter ended.
- Principal risks include clinical-trial and regulatory uncertainty, patient enrollment and trial delays, safety findings, dependence on contract manufacturers and research organizations, financing needs and potential dilution, the pending merger, and possible effects of COVID-19, geopolitical events, inflation and market volatility. The company also relies on its Biocon license and supply arrangements for itolizumab.
- The filing reports no legal proceedings. Management concluded disclosure controls and procedures were effective at the reasonable-assurance level as of September 30, 2022, with no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether the Metacrine merger closes, its final net cash and exchange ratio, and the resulting financing, debt and dilution impact.
- Actual cash burn and available runway, particularly if the merger does not close or clinical spending changes.
- Progress, enrollment, safety and final results for the EQUATOR Phase 3 trial and the lupus nephritis, EQ101 and EQ102 programs; interim findings may change as data mature.
- Timing and amount of scheduled term-loan principal payments, and any negotiated replacement or assumed debt terms.
- Potential Bioniz milestone obligations and the continuing terms and diligence requirements of the Biocon license.